articleTop 1% cited

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Journal of Clinical Oncology · 2003 · Vol. 21(14) · pp. 2636–2644

Nicholas J. Vogelzang✉(Heidelberg University)James J. Rusthoven(Heidelberg University)James T. Symanowski(Heidelberg University)Claude Denham(Heidelberg University)E. Kaukel(Heidelberg University)Pierre Ruffiè(Heidelberg University)U. Gatzemeier(Heidelberg University)Michael Boyer(Heidelberg University)Salih Emri(Heidelberg University)Christian Manegold(Heidelberg University)Clet Niyikiza(Heidelberg University)Paolo Paoletti(Heidelberg University)

View via DOI Publisher page

Abstract

Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cisplatin alone in patients with malignant pleural mesothelioma. Addition of folic acid and vitamin B12 significantly reduced toxicity without adversely affecting survival time.

Occupational and environmental lung diseases Pleural and Pulmonary Diseases Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPemetrexedMedicineCisplatinMesotheliomaInternal medicineChemotherapyOncologySurgeryGastroenterologyUrology

MeSH terms

PemetrexedAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinDose-Response Relationship, DrugDrug Administration ScheduleFemaleGlutamatesGuanineHumansMaleMesotheliomaMiddle Aged

Citations

3,045

FWCI

83.34

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy